Literature DB >> 318973

Fosfomycin and plasmidic resistance.

F Baquero, M López-Brea, A Valls, T Cañedo.   

Abstract

60 fosfomycin-resistant strains of gram-negative bacilli are submitted to conjugation experiments using as recipient cell E. coli K12 which is nalidixic acid resistant. After mating, the number of fosfomycin-resistant E. coli K2 colonies growing on selection plates containing nalidixic acid and fosfomycin never surpassed the normal rate of mutation for fosfomycin-resistance of the recipient strain. In 65% of the experiments, plasmidic resistance to other antimicrobials was transferred to E. coli K12, but was never accompanied by demonstrable fosfomycin resistance. High rate of normal mutation of recipient strain is signaled as the main problem for detecting the plasmidic nature of fosfomycin resistance. With our criteria regarding this fact we have been unable to confirm the plasmidic nature of fosfomycin resistance.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 318973     DOI: 10.1159/000222039

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  4 in total

1.  Novel Fosfomycin resistance of Pseudomonas aeruginosa clinical isolates recovered in Japan in 1996.

Authors:  M Shimizu; F Shigeobu; I Miyakozawa; A Nakamura; M Suzuki; S Mizukoshi; K O'Hara; T Sawai
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

Review 2.  Fosfomycin: an old, new friend?

Authors:  M Popovic; D Steinort; S Pillai; C Joukhadar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-14       Impact factor: 3.267

3.  In vitro investigations with fosfomycin on Mueller-Hinton agar with and without glucose-6-phosphate.

Authors:  H Grimm
Journal:  Infection       Date:  1979       Impact factor: 3.553

4.  [In vitro effect of fosfomycin against Pseudomonas aeruginosa compared to carbenicillin, gentamycin and polymyxin B].

Authors:  R Ansorg
Journal:  Infection       Date:  1978       Impact factor: 3.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.